Allumia Ventures

Allumia Ventures is a healthcare-focused venture capital firm that invests in commercial-stage companies leveraging technology to solve pressing challenges in the sector. The firm targets digital health, tech-enabled healthcare services, and MedTech solutions, typically at Series A through C stages, with initial investments of $5-10 million and up to $15 million total per company. It prefers to lead or co-lead deals, often taking board seats, and emphasizes both financial returns and strategic support through its network of limited partners including major healthcare organizations.

Originally launched as Providence Ventures in 2015 amid the post-HITECH and Accountable Care Act boom in digital health, the firm was created within Providence, one of the largest U.S. health systems, to bridge fragmented innovation and stakeholder needs. In January 2025, it spun out to become independent Allumia Ventures following a first close of its third fund, anchored by a $150 million commitment from Providence over 10 years. This evolution allows Allumia to partner with additional mission-driven healthcare entities while maintaining deep ties to its founding network for enhanced due diligence and adoption.

The firm manages a portfolio of 28-29 companies, with 10 successful exits, where every portfolio company has engaged with its LP base such as Providence. Notable investments and news highlights include backing Affect Therapeutics' $26 million Series B, DexCare's $20 million Series A spinout, TailorMed's growth financing, Lyra Health's multiple rounds leading to unicorn status, and others like Kno2, RxRevu, and Omada Health's IPO. These span mental health, interoperability, financial barriers to care, and digital access tools.

Led by Managing Partner Jeff Stolte, Partners Dan Galles and Branden Fini, Vice Presidents Jen Lee and Christina Warner, CFO Craig Slutzkin, and Project Manager Amber Hill, the team brings over a decade of healthcare VC experience. An inaugural advisory board features experts like Sandra Clarke (former Blue Shield exec), Susan Huang MD (Providence Clinical Network CEO), Cathy Jacobson (former Froedtert Health CEO), and Ben Zaniello MD (Best Buy Health). This blend of investment acumen and operational healthcare knowledge drives the firm's dual focus on returns and impact.